USAQ · QHSLab, Inc.

QHSLab's fiscal 2025 results demonstrate significant operational and financial improvement, with revenue growth of 26% to $2.69 million driven primarily by strong adoption of the Integrated Service Program (ISP), which grew 74% year-over-year to $1.12 million. The company's margin expansion to 67.3% reflects a favorable shift toward higher-margin digital health services and improved cost structure. Management highlighted that 2025 marked an important year of operational progress and financial strengthening, with the company transitioning to profitability with net income of $457,417 compared to a net loss in 2024. The balance sheet was significantly strengthened through debt restructuring, including a $1.15 million gain from debt extinguishment, reduction of interest expense by nearly half to $237,413, and current liabilities decreasing from approximately $2.4 million to $450,000. CEO Troy Grogan emphasized that the company's focus for 2026 includes expanding the physician network through targeted sales hiring, scaling digital health infrastructure, and positioning QHSLab as a trusted partner for primary care practices implementing population-based screening and care management programs. The company operates across healthcare solutions including digital health decision-support tools, allergy diagnostics, and allergen immunotherapy services, with revenue streams diversified across diagnostics, therapeutics, and digital health services.